NASDAQ:ARWR

Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis

Arrowhead Pharmaceuticals logo
$41.36 -2.29 (-5.24%)
Closing price 03:59 PM Eastern
Extended Trading
$41.37 +0.01 (+0.02%)
As of 05:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR)

Advanced

Key Stats

Today's Range
$41.17
▼
$44.80
50-Day Range
$42.99
▼
$82.85
52-Week Range
$37.43
▼
$95.49
Volume
3.91 million shs
Average Volume
2.27 million shs
Market Capitalization
$5.85 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$98.71
Consensus Rating
Moderate Buy

Company Overview

Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues.

The company’s research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.

Founded in 1989 as Arrowhead Research Corporation, the company adopted the name Arrowhead Pharmaceuticals in 2015. It is headquartered in Pasadena, California.

AI Generated. May Contain Errors.

Arrowhead Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
54th Percentile Overall Score

ARWR MarketRank™: 
2.71156219997 of 5 stars

Arrowhead Pharmaceuticals scored higher than 54% of companies evaluated by MarketBeat, and ranked 496th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Arrowhead Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 1 strong buy rating, 10 buy ratings, 3 hold ratings, and 1 sell rating.

  • Upside Potential

    Arrowhead Pharmaceuticals has a consensus price target of $98.71, representing about 138.7% upside from its current price of $41.36.

  • Amount of Analyst Coverage

    Arrowhead Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Arrowhead Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Arrowhead Pharmaceuticals are expected to grow in the coming year, from ($5.07) to ($3.77) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Arrowhead Pharmaceuticals is -8.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Arrowhead Pharmaceuticals is -8.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Arrowhead Pharmaceuticals has a P/B Ratio of 114.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Arrowhead Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    8.53% of the float of Arrowhead Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Arrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 8.54.
  • Change versus previous month

    Short interest in Arrowhead Pharmaceuticals has recently increased by 5.70%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Arrowhead Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Arrowhead Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Arrowhead Pharmaceuticals has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 22 news articles for Arrowhead Pharmaceuticals this week, compared to 8 articles on an average week.
  • Search Interest

    9 people have searched for ARWR on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.
  • MarketBeat Follows

    Only 5 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -38% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Arrowhead Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    3.60% of the stock of Arrowhead Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    62.61% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Arrowhead Pharmaceuticals' insider trading history.
Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ARWR Stock News Headlines

This is likely to EXPLODE
Dr. Martin D. Weiss, founder of Weiss Ratings and a two-time Congressional witness on financial institution risk, is warning of a looming $3 trillion threat in today's financial system. He says the same ratings agency practices that preceded the 2008 crisis are repeating themselves, while regulators stay quiet about the risks.tc pixel
See More Headlines

ARWR Stock Analysis - Frequently Asked Questions

Arrowhead Pharmaceuticals' stock was trading at $66.39 at the start of the year. Since then, ARWR shares have decreased by 37.7% and is now trading at $41.3630.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) posted its quarterly earnings results on Tuesday, August, 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by $0.13. Arrowhead Pharmaceuticals's revenue was up 171.0% compared to the same quarter last year.
Read the conference call transcript
.

Arrowhead Pharmaceuticals' top institutional investors include Baker BROS. Advisors LP (1.21%), Fisher Asset Management LLC (0.63%), Goldman Sachs Group Inc. (0.60%) and Pictet Asset Management Holding SA (0.54%). Insiders that own company stock include Christopher Richard Anzalone, Patrick O'brien, Kenneth Allen Myszkowski, James C Hamilton, Daniel Joseph Apel, Martin Javier San, Douglas B Given, Tracie Oliver, Michael S Perry, Mauro Ferrari, William D Waddill, Hongbo Lu, Victoria Vakiener and Adeoye Y Olukotun.
View institutional ownership trends
.

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Arrowhead Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Bristol Myers Squibb (BMY), Gilead Sciences (GILD) and AbbVie (ABBV).

Company Calendar

Last Earnings
8/04/2026
Today
11/20/2026
Next Earnings (Estimated)
2/04/2027
Fiscal Year End
9/30/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ARWR
CIK
879407
Employees
1,062
Year Founded
2001

Price Target and Rating

High Price Target
$126.00
Low Price Target
$46.00
Potential Upside/Downside
+138.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
15 Analysts

Profitability

EPS (Trailing Twelve Months)
($5.11)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$724.21 million
Net Margins
-160.64%
Pretax Margin
-160.58%
Return on Equity
-172.62%
Return on Assets
-37.51%

Debt

Debt-to-Equity Ratio
16.61
Current Ratio
4.14
Quick Ratio
4.11

Sales & Book Value

Annual Sales
$450.82 million
Price / Sales
12.97
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.36 per share
Price / Book
114.90

Miscellaneous

Outstanding Shares
141,370,000
Free Float
136,279,000
Market Cap
$5.85 billion
Optionable
Optionable
Beta
1.34

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

This page (NASDAQ:ARWR) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners